DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin in combination with Pertuzumab with or without Toripalimab neoadjuvant therapy in patients with HER2-positive breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dobrowolny udział i podpisanie zgody na uczestnictwo
- •Wiek 18 lat lub więcej
- •Potwierdzony inwazyjny rak piersi, stadium T2-3 (guz większy niż 2 cm), bez przerzutów do narządów odległych
- •Guz z dodatnim markerem HER2 (potwierdzony testami laboratoryjnymi)
- •Planowane operacyjne leczenie raka piersi, bez wcześniejszej chemioterapii
- •Co najmniej jeden mierzalny ognisk zmian
- •Prawidłowa funkcja serca (frakcja wyrzutowa lewej komory ≥55%)
- •Prawidłowe wyniki badań krwi i funkcji nerek (hemoglobina ≥90 g/L, neutrofile ≥1,5×10⁹/L, płytki ≥100×10⁹/L)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, China
Trial contact
Jianmin Fang, Ph.D
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.